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MICRO COMPUTED TOMOGRAPHY ASSESSMENT OF TUMOR SIZE IN          
BREAST CANCER COMPARED TO HISTOPATHOLOGICAL EXAMINATION 
 
WAFA MOWAFAK SARRAJ 
 
ABSTRACT 
Purpose: The purpose of this study was to assess the ability of Micro Computed 
Tomography (Micro CT) to measure primary tumor size in breast lumpectomy 
specimens, as compared to the histopathological measurement. 
Methods: This was a diagnostic study involving women who were scheduled to have 
breast lumpectomy surgery at the Massachusetts General Hospital (MGH) Department of 
surgery from June 2011 – September 2011. Those who met the study eligibility criteria 
were recruited to participate in the study. The study was approved by the MGH 
Institutional Review Board (IRB). All the participants provided consent prior to their 
participation in the study. The lumpectomy specimens of 45 subjects were scanned by 
Micro CT scan for no longer than 15 minutes, they were then delivered to the gross 
pathology lab for processing via the standard pathological protocol. Later on, the 
maximum dimension of the invasive breast tumor was obtained from the Micro CT image 
and was compared to the corresponding pathology report for each subject. 
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Results: We found that Micro CT tends to overestimate the breast malignant tumor size. 
However, there were few differences in T-stage classification between Micro CT and 
pathology. Overall, Micro CT demonstrated good agreement with pathological tumor size 
and staging. For Invasive ductal carcinoma, Micro CT showed a substantial agreement 
with pathological tumor size and staging. However, Micro CT showed no agreement with 
pathological tumor size and staging for invasive lobular carcinoma.  
Conclusions: Micro CT is a promising modality in measuring and staging the invasive 
ductal carcinoma. 
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1. INTRODUCTION 
 
 The breasts are tear shaped glands that are located on the muscle of chest wall. 
They extend anteriorly from the clavicle to the breastbone (sternum), and into the medial 
walls of the axilla. 1 The breast is covered by deep and superficial fasciae, which are 
connected by fibrous bands known as Copper suspensory ligaments that work as a mesh 
to support the breast. 1,2 Each breast is covered by skin and contains glandular tissue and 
fatty tissue. The glandular tissue, known as parenchyma consists of 15 to 20 lobes. Each 
lobe is divided into small lobules, which consist of alveoli that produce milk. 1 The 
glandular lobe and lobules are drained by an equal number of lactiferous ducts that 
converge and open at the tip of the nipple (Figure 1). The nipple is surrounded by a dark, 
round area called the areola. The areola contains Montgomery glands, which secrete fluid 
to lubricate the nipple and the areola during breastfeeding. 1 The breast parenchyma is 
separated by stroma that contains connective tissue, varying amounts of fat, blood and 
lymphatic vessels, and nerves. The skin of the breast contains hair follicles, sebaceous 
glands, and sweat glands. 1, 2 
 
 
Figure1. Breast Anatomy   
(Imported from www.cancer.gov) 
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The size and shape of the breast depends mainly on the ratio of fatty tissue to the 
glandular tissue and the strength of the Cooper’s suspensory ligaments. 1,2 During puberty 
and adulthood, the breast is composed mainly of glandular tissue with small amounts of 
fatty tissue. The glandular contents of the breasts increase significantly during pregnancy 
and lactation in order to produce milk. 1 However, as women get older and approach 
menopause, the ligaments become relaxed and the ratio of fatty tissue to glandular tissue 
increases causing a sagging in shape known as breast ptosis. 1,2 
 
The lymphatic system of the breast is composed of lymph nodes and lymphatic 
vessels. 1,3 There are three groups of lymph nodes that drain each breast: the apical group 
located just above the axilla; the supraclavicular group located above the clavicle; and, 
the internal mammary group located along the breastbone. 1,3 The axillary lymph nodes 
are arranged in three levels according to their relation to the Pectoralis minor muscle: 
Level I nodes are located laterally to the lateral border of the muscle; level II nodes are 
located just behind the muscle; level III nodes are located medially to the medial border 
of the muscles. 1, 3 Most of the lymphatic vessels of the breast drain into the axillary 
lymph nodes; approximately 97% of the lymph flows into the axillary lymph nodes, 
while 3% of the lymph flows into the internal mammary lymph nodes.4 
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1.2 Breast Cancer 
 
Breast Cancer is the most common type of cancer affecting women worldwide. It 
is estimated that 12.3% (one in 8) of women in the United States would be affected by 
breast cancer in their lifetimes. 3 This year, an estimated 232, 670 new cases of invasive 
breast cancer and 62,570 new cases of non-invasive cancer diagnoses are expected in this 
country. 3 The breast cancer incidence rate declined significantly by 7% between 2002-
2003 after more than 20 years of high incidence rates: this was thought to be due to 
decreased intake of hormonal replacement therapy (HRT) among women after the results 
of a large cohort study published in 2002 called Women’s Health Initiative. 5 The results 
of the study suggested an association between HRT and increased breast cancer risk. 
However, the incidence rate has remained constant over the last few years.3,5   
Breast cancer is responsible for 3% (one in 36) of deaths in women in the United 
States. 3 About 40,000 women in the United States are expected to die from breast cancer 
in 2014. 3 However, breast cancer death rates have decreased in recent years, mainly in 
women younger than 50 because of earlier detection from more comprehensive screening 
as well as improved quality of treatment. 3 More than 2.8 million women in the United 
States are breast cancer survivors. 3 
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There are many risk factors that contribute to breast cancer development. These 
factors can be divided into non-modified and modified risk factors.  
The non-modified risk factors are the most significant risk factors, and include 
aging, being a woman, and early menarche (before age 12) or late menopause (after age 
55). 3,6 In addition, Non-Hispanic White women are more likely to develop breast cancer 
compared to African American women. However, African American women are more 
likely to die from breast cancer compared to non-Hispanic women because they tend to 
have aggressive tumors at the time of diagnosis. 3,6 Other ethnicities including Hispanic, 
Asian, and Native Americans have low incidence and death rates from breast cancer 
compared to non-Hispanic White and African American women. 3,6 
 
Approximately 5% to 10% of breast cancer cases are triggered by genetic 
mutations inherited from one of the parents (father or mother). 3   There are many gene 
mutations that cause breast cancer. However, the most common mutations are located in 
the BRCA1 and BRCA2 genes. 3,6 These genes normally prevent formation of cancer 
cells by producing a protein that stops the growth of the abnormal cells during the cell 
cycle. 3 The BRCA mutations are often found in women of Ashkenazi Jewish descent. 3,6 
Women with the BRCA1 mutation have an 80% risk of developing breast cancer, while 
those with the BRCA2 mutation have a 45% risk of developing breast cancer during their 
lifetime 6 These women tend to develop breast cancer before age of 50. Additionally, 
women who carry BRCA mutations have an increased risk of developing ovarian cancer 
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during their lifetime. 6 However, 90% of breast cancer cases are caused by the interplay 
between environmental and genetic factors. 3,6  
 
The risk of developing breast cancer is increased if a first-degree relative (mother, 
sister, or daughter) has or has had breast cancer. 3 The risk of developing breast cancer 
doubles if the number of the affected first-degree relatives is greater than one. 3, 
 
Women with a previous history of either breast cancer or benign proliferative 
breast disease with atypical cells (atypia) such as fibrocystic disease are at higher risk of 
developing breast cancer. The risk of breast cancer is four to five times greater in women 
with atypical proliferative breast lesions. 3,6 
 
Breast tissue density is defined as the ratio of fibroglandular tissue to fatty tissue 
within the breast. (1) The more fibroglandular tissue in the breast, the higher its density. 
High breast density can be inherited; it can also be developed during pregnancy or as a 
result of HRT. 3,6 The risk of breast cancer is increased 4-6 fold in women with high 
breast density because dense breast tissue contains larger number of breast cells that can 
proliferate to cancer cells. 3,6   
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Women who received chest radiation to treat certain types of lymphoma (blood 
cancer) are at very high risk of developing breast cancer, especially if they received it 
during adolescence. 3 However, chest radiotherapy after age 40 is less likely to increase 
breast cancer risk. 3,6 
 
The modified risk factors (lifestyle risk factors) include taking HRT, which is 
used to treat menopause. HRT slightly increases the risk of breast cancer in women with 
long-term use (10 years). 3,6 Women who have taken birth control pills have a 10%-30% 
greater risk of developing breast cancer. 6 However, breast cancer risk vanishes in women 
who have stopped taking birth control pills for 10 years or more. 6 The risk of developing 
breast cancer is also associated with being overweight, not exercising, not having 
children, not breastfeeding, and drinking alcohol (2-5 drinks/day). 3,6 
 
In general, it is important to understand that women can develop breast cancer 
even without these risk factors. The only way to reduce the breast cancer death rate is 
through early detection screening programs. 3,6 
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1.3 Type of breast Cancer 
 
 There are many types of breast cancer, some of which are rare. Most of the 
literature classifies breast cancer into non-invasive (in situ) and invasive cancer. 3,7 Breast 
cancer can be made of a single type or a mixture of different types of cells. However, 
before listing these types, it is important to understand the difference between non-
invasive and invasive cancers. Non-invasive (in situ) cancer is when the cancer cells are 
localized either inside the ducts or the lobules and have not invaded the deep structure of 
the breast or other parts of the body.3 
 
There are two types of non-invasive cancer: 1) Ductal carcinoma in situ (DCIS): 
occurs when the cancer cells arise from the cells that line the ducts, and the cells have not 
spread out of the ductal wall (Figure 2, Appendix 1). 3 One out of 5 women diagnosed 
with breast cancer are diagnosed with DCIS. 3,7   DCIS often presents with calcification, 
and as calcification is detectable on mammography screening, approximately 40% of 
abnormalities diagnosed screened populations are DCIS. 8   It is believed that women with 
untreated DCIS will develop breast cancer in the same breast. 3, 7  
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2) Lobular carcinoma in situ (LCIS): occurs when the cancer cells arise from the 
lobules, and cancer cells have not spread out of the lobules (Figure 3, Appendix 2).3 
Detection of LCIS by mammogram is challenging because it is rarely associated with 
calcification. 7 Women with untreated LCIS have a tendency to develop cancer, mainly 
invasive lobular cancer, in both breasts. 7 However, there is a chance of developing 
invasive ductal cancer because LCIS occurs particularly in the terminal duct lobular unit. 
3,7 
Invasive cancer occurs when the cancer cells grow outside either the duct or the 
lobules by penetrating the basement membrane of the ducts and the lobules. 3 These 
cancer cells can also invade the deep structure of the breast and spread to other body 
organs. 3   The invasive cancers include 
 
1) Invasive ductal carcinoma (IDC): The most common histological type of 
invasive breast cancer, an IDC accounts for approximately 70% - 80% of breast cancer 
cases. 7 IDC is easy to diagnose clinically and mammographically because the tumor 
forms a desmoplastic reaction, which is when normal breast fatty tissue is replaced by 
excessive fibrous tissue causing fibrosis at the primary tumor site. This reaction will form 
a hard palpable mass that can be detected upon the physical examination and 
mammography (Figure 4, Appendix 3). 3,7 
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2) Invasive lobular carcinoma (ILC): ILC accounts for only 5% -10% of all breast 
cancer cases. 7 ILC is hard to diagnose clinically and mammographically because it tends 
to grow in a diffuse pattern without forming a desmoplastic reaction. Hence, often no 
mass will be formed. 7 About 10%-20% of ILC cases are multifocal and bilateral (Figure 
5, Appendix 4). 3,7 There are other types of breast cancer that appear less frequently. 
These include inflammatory, medullary, mucinous, and tubular carcinomas. 7 
 
1.4 Diagnosis of Breast Cancer  
 
When a patient presents with symptoms of breast cancer or has a suspicious lesion 
upon screening mammography, she undergoes diagnostic mammography. 3 This is similar 
to a screening mammography, except that more images of the suspicious lesion are taken; 
these images sometimes are viewed with magnification to assess the small abnormal 
breast lesions. 3,8 
 
Ultrasound is usually used in patients with dense breast tissue such as pregnant 
patients or patients under the age of 30. Ultrasound can distinguish between benign 
(cystic) and malignant (solid) lesions. 3,8 Although there are many methods to diagnose 
the breast cancer clinically such as physical examination, diagnostic mammography, 
breast ultrasound, and magnetic resonance imaging, approximately 60% of lesions that 
are identified as malignant by physical examination and imaging modalities are benign on 
biopsy, while 30% of lesions that are identified as  benign by physical examination and 
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imaging modalities are malignant on biopsy. 9 Because of this, breast biopsy is the gold 
standard method to confirm a diagnosis of breast cancer.9 
 
What is a biopsy? A biopsy is a sample taken from a suspicious lesion to be 
examined under a microscope by a pathologist. 9   There are several types of biopsies. The 
difference between each one is the amount of removed tissue. For example, in a fine 
needle aspiration biopsy (FNA), the doctor uses a very fine needle (22-25 gauges) to take 
a biopsy, while in a core needle biopsy (CNB); a thick needle (8-14 gauges) is used to 
remove the tissue. 3,8,9 Both procedures are performed under local anesthesia. Although 
the FNA is the easiest method to perform, CNB is still preferred because a larger sample 
of the lesion is removed, allowing for a more precise diagnosis. 3,9 
 
When the CNB is inadequate to perform diagnosis, a surgical (open) biopsy is 
required. (3) A surgical biopsy is a more invasive method. It involves removing a large 
amount of tissue. Because of this, formation of a scar is more likely to occur. The scar 
can lead to difficulties in interpreting the subsequent images of the lesion. 3, 9 
 
In cases where the mass is not palpable, the doctor may use either mammogram or 
ultrasound to guide the biopsy. 3 Alternatively, a metal clip or wire may be inserted into 
the lesion to help the surgeon and the pathologist to localize the tumor accurately in a 
mammography-guided procedure known as wire needle localization. 3, 9    
	  11 
The doctor chooses the type of biopsy based on the size of the lesion, the location 
of the lesion, the patient’s medical history, and the patient’s preference. 3 
 
Once the biopsy is received, a pathologist examines the specimen grossly and 
microscopy to determine if it is benign or malignant. If it is malignant, then the 
pathologist will determine the lesion type, if there is any invasion to the surrounding 
structure (blood vessels and lymphatic vessels), and whether the mass was completely 
excised or if there are any malignant cells in the specimen’s margins. 3, 8 
 
The pathologist will also determine the grade of the cancer. The tumor grade is an 
important prognostic factor for breast cancer and is essential in determining whether or 
not further treatment is required after the surgery. 3,10   The grading system is based mainly 
on the similarity between the cancer tissue and normal breast tissue and the growth rate 
of the cancer cells (Table 1). The grading system is divided into three grades. Grade I 
indicates that the cancer resembles normal breast tissue (well differentiated) and exhibits 
a slow growth rate. Grade II indicates that the cancer somewhat resembles normal breast 
tissue (moderately differentiated) and exhibits a moderate growth rate. Grade III indicates 
that the cancer does not resemble normal breast tissue (poorly differentiated) and exhibits 
a fast growth rate of the cancer cells. 3,10 A higher grade indicates a worse prognosis. 
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The pathologist will examine the presence (positive result) or absence (negative 
result) of estrogen (ER), progesterone (PR) and HER-2/neu receptors. 3 The presence of 
these receptors will improve the prognosis through specific treatments. These treatments 
are directed toward tumors dependent on these receptors. For example, patients who are 
ER, PR positive will receive hormonal therapies. Those who are HER-2/neu positive will 
receive Herceptin. 3  
 
 
Table 1. Breast Cancer Grading System 10 
 
1.5 Staging of breast cancer  
 
The breast cancer staging system is a standardized system. It is used to assess the 
spread of cancer in the body among breast cancer patients. 3 The purpose of the staging is 
to determine the appropriate treatment for the patients and to predict the outcome of the 
cancer. 1,3 It is established by the American Joint Committee on Cancer (AJCC). 1,3 Every 
6-8 years, AJCC updates the staging system based on the latest research on tumor 
behavior. 1 
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The staging must be determined before offering any treatments to the patients. 
There are two types of staging: clinical staging and pathological staging. Clinical staging 
is based on the clinical examination and imaging studies performed before the surgery. 3 
It helps the physicians decide if a patient needs to receive chemotherapy or radiotherapy 
before undergoing surgery. 3 Pathological staging is based on the surgical results and is 
more precise than clinical staging because the pathologist can examine the cancer 
closely.3 
 
The TNM Classification of the malignant tumor is the most commonly used 
cancer staging system. 3 The TNM staging system is composed of three variables: T for 
the primary tumor size: N for lymph node status: and M for the distant metastases. 1,11 If 
the pathological staging was used, then TNM will be labeled as pTNM (pathology TNM). 
For clinical staging, it will be labeled as cTNM (clinical TNM). 11 
 
Once TNM information is obtained, then the cancer is categorized into one of five 
staging groups, each of which is represented by a Roman numeral from I to IV. 11 
The TNM staging system is complex (see Appendix 5): a simple version of the 
staging is provided below: 
 
            Stage 0: Non- invasive cancer. It is based on the type of the in situ disease (DCIS,  
 LCIS, and Paget disease), not the size of the tumor 
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Stage I (early stage): The tumor is two cm or less along the longest axis and has 
not spread out of the breast, or the tumor is less than two cm across with small foci of the 
cancer in the axially (underarm) lymph nodes, with no distant metastases. 
 
Stage II (early stage):  The tumor is two cm along the longest axis, and it has 
spread either to the axillary (under arm) or internal mammary (near breast bone) lymph 
nodes, or the tumor is larger than two cm and less than five cm in across, and has/has not 
spread to the lymph nodes, or the tumor is greater than five cm in across and has not 
spread beyond the breast. No distant metastases are present. 
 
Stage III (advanced local stage): The tumor is more than five cm across and has 
spread to the axillary lymph nodes, or the cancer has extensively spread to either the 
axillary or internal mammary lymph nodes, or the tumor has spread to a surrounding 
structure such as the chest wall. 
             Stage IV: Metastatic cancer, where a tumor of any size has spread to the body’s 
organs. 
 
A patient with stage 0 has a 100% 5-year survival rate, while a patient with stage 
IV has a 22% 5-year survival rate. 3 However, there are other factors that influence the 
breast cancer prognosis such as age, general patient health, histological tumor type, tumor 
grade, and hormonal receptor status. 1 Unfortunately, some of these variables such as 
hormonal receptor status and tumor grade are not included in the staging system 
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1.5 Breast Cancer Size Measurements Methods 
The primary tumor size is an essential factor in determining the treatment 
regimens and predicting the prognosis of a breast cancer patient. A patient with a tumor 
size smaller than 1 cm has 93% 5-year survival rate, while a patient with a tumor size 
larger than 5 cm has a 63% 5-year survival rate. 12 
 
Since 1969, many studies have demonstrated a strong association between breast 
tumor size and disease progression. 13,14,15,16,17 These observations eventually led the 
American Joint Committee on Cancer (AJCC) and The Union for International Cancer 
Control (UIAC) to establish the TNM staging system. 11 The categorization of malignant 
tumor size in this system is based on the measurement of the largest dimension of the 
malignant tumor. 11 
 
The primary tumor size (T) in the TNM system is categorized into seven groups 
(see Appendix 5). A simple version is provided below: 
 
Tx Tumor size cannot be assessed 
T0 No Tumor  
Tis 
 
T1 
Carcinoma in situ. This group is divided into three groups based on the 
type of the in situ disease 
Tumor is less than or equal to 2 cm. This group subcategorized into four 
groups based on the actual size of the tumor.  
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T2 
T3 
Tumor is greater than 2 cm and less than 5 cm 
Tumor is larger than 5 cm 
T4 Tumor of any size. This group is subcategorized into 4 groups based on 
the site of distant metastasis. 
 
Several different methods exist to measure the breast tumor size, including 
clinical examination, breast ultrasound, mammography, and magnetic resonance imaging 
(MRI). However, pathological assessment of the malignant tumor size is still considered 
the gold standard. 18,19 
 
1.5.1 Pathological Examination 
Once the specimen is received, it is examined grossly and microscopically. Most 
of the time the specimen is received fresh, where no fixative solution has been added. 
During the gross examination, a complete description of the specimen and the tumor 
(shape, size, consistency, color) is documented. If the specimen margins are oriented 
through surgical stitches during the surgery, then the edges are inked with six different 
colors during the gross examination. If the specimen is not oriented, it is entirely inked 
black. Then the specimen is cut along its longest axis. These slices are placed in small 
plastic cassettes, which hold the tissue as it is processed into paraffin blocks. 3,20 
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How is the tumor size measured? During the gross examination, three-
dimensional measurements of the tumor are taken after cutting the specimen into 
sections. The tumor is seen clearly after an initial slice, allowing for an accurate 
measurement. The measurements are obtained using a plastic ruler. However, only the 
greatest dimension is used to classify the malignant tumor size in the TNM staging 
system. The measurements are recorded and documented using 0.1centimeter 
increments.19. When the invasive tumor cannot be seen by the naked eyes or when 
contains a significant amount of in-situ component that will cause an overestimation of 
gross tumor size, a microscopic measurement is required and recommended by the 
College of American Pathologists (CAP). 19 
 
The microscopic assessment is obtained by measuring the extension of the 
malignant tumor in six directions: medial, lateral, anterior, posterior, superior, and 
inferior. The malignant tumor size is obtained by multiplying the number of the slides 
that show invasive malignant tumor by thickness of each tissue section (Figure 6). 20 In 
cases where the greatest dimension of invasive tumor is found in only one slide, this 
dimension would be considered the maximum tumor size. 20  
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Figure 6. Pathological measurement of Breast Malignant Tumor Size 20 
 
 
1.5 Micro Computed Tomography Scan (Micro-CT) 
 
Micro CT scan is a non-invasive X-ray technology that provides high-resolution 
(10 µm) three-dimensional (3D) images of ex-vivo specimens. 21 Jim Elliott created the 
first Micro CT scanner in early 1980. 22 However, Feldkamp et al. were the first to 
develop a reconstruction algorithm for the cone beam X-ray, and they used this 
technology to evaluate the fine structure of bone. 23, 24 Recently, Micro CT has been used 
in animal, bone structure, and blood vessel studies. About 58% of the Micro CT 
publications in PubMed involved bone, 16% involved blood vessels, and 26% involved 
other applications. 21 
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There are three types of Micro CT, each featuring different scan resolution: mini-
CT, micro CT, and nano-CT. These scanners can image objects ranging in size from 
whole animals (small rodents) to single cells (Figure 7). 21 
 
 
Figure 7. Different types of Micro-CT. (20) 
 
These machines come in different sizes, ranging from portable, lightweight, and 
tabletop-sized to heavy and room-sized. Unlike clinical computed tomography, which is 
used to scan the human body, Micro CT can only scan small animals, and specimens up 
to 20 centimeters in size. 
 
A Micro CT machine is composed of an X-ray source, a flat- panel X-ray 
detector, a rotatory stage harboring the specimen, and software for image reconstruction. 
21 The Micro-CT X-ray source is composed of a tube that contains a pair of electrodes 
called a cathode and an anode. 25 The cathode is negatively charged and contains a 
filament that releases energy upon introduction of electric current. Cathode energy is 
released in the form of accelerated electrons. 25 The anode, which consists of a tungsten 
(type of metal) disc, is located in the other end of the tube. 25 When the electrons are 
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released from the cathode, they are attracted to the positive anode and come in contact 
with the tungsten, resulting in the production of X-rays. 25 
 
The Micro-CT scanner uses a flat panel detector, which is based on solid-state 
integrated circuit technology. This technology has also been used in digital cameras. 26 
There are two types of flat panel detectors: direct and indirect. The direct detector is 
energy–integrating and is made of amorphous selenium. It can convert an X-ray into 
charge due to a photoconductive outer layer. 21, 27  The indirect detector (photon-counting 
detector) is made of amorphous silicon, photodiodes, and a scintillator, which is made of 
gadolinium oxysulfide or cesium iodide. 26 The scintillator is located in the outer layer of 
the detector unit. The main function of the scintillator is to convert the X-rays to visible 
light photons. Once the photons hit the photodiodes, they are converted to electrons. 
These electrons activate the pixels (the smallest element in the picture) in the amorphous 
silicon. The activated pixel produces data that are converted to high-resolution images by 
the computer. 26 The most commonly used detector in Micro-CT is the indirect detector. 
21, 25 3D images are then reconstructed from 2D images using specific reconstruction 
software. 
 
The specimen is placed horizontally on a rotatory stage located between the X-ray 
source and the detector, while the X-ray source and the detector are fixed. Once X-rays 
are generated from the tube, they pass through the specimen. In order to obtain 
radiographic projections (the specimen X-ray shadow) from different angles, the scanned 
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specimen is rotated around its vertical axis. Each projection is then captured by the flat-
panel detector as a two-dimensional (2D) image. Then 3D reconstruction software is 
applied to obtain the three-dimensional image. This software helps to visualize not only 
the external and the internal surface of the specimen, but also its fine structures. 21,25,28 
 
 
 
Figure 8. Micro-CT components and mechanism. 26 
 
The reconstructed images can be previewed through dedicated software. Because 
of the high-resolution images, three-dimensional measurement and volume rendering of 
the specimen can be obtained by using specific tools in the software.  
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The study rationale: 
Although there are many modalities to measure the malignant tumor size such as 
breast ultrasound, mammography, and MRI, the pathological assessment remains the 
gold standard. 18 There are different elements that could affect the accuracy of 
pathological tumor measurement such as diligence of the measurement by the 
pathologist, fixation of tissue in the formalin and the histological type, and the growth 
pattern of the tumor.19 In particular, the tumor type and the growth pattern of the tumor 
can change the tumor size staging classification.19 For example, invasive ductal 
carcinoma can be measured easily in the gross examination because it usually forms a 
mass that has circumscribed irregular borders. On the other hand, invasive lobular 
carcinoma tends to grow in a diffuse pattern, without formation of desmoplastic stroma. 
Hence, no mass will be formed. Because of this, measuring the size of ILC is often 
challenging. 19(Figure 9) 
 
 
(A) IDC                                                        (B) ILC 
               Figure 9. Differences between IDC and ILC grossly 
                         (Imported from http://www.pathologyoutlines.com) 
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Because of these factors, the pathologist will often try to correlate the tumor size 
measurement with corresponding image to confirm the final measurement of the tumor 
size. A one-millimeter variation in the measurement can lead to a change in T staging 
classification, which in turn will alter the patient’s treatment options. For example, if a 
tumor measures 1.1 cm in its maximum dimension instead of 1.0 cm, its T stage 
classification would be T1c to T1b. This could lead the clinicians to offer the patient 
adjuvant chemotherapy. 19 Numerous studies have been conducted to correlate the 
pathology tumor measurement with different modalities such as ultrasound, 
mammography, and Magnetic Resonance Imaging (MRI); however, these studies showed 
conflicting and inconsistent results. 29-37 Hence, none of these modalities are accepted as 
the standard for tumor size measurement.  
 
A Micro computed Tomography (Micro CT), a relatively a new x-ray imaging 
modality, has the ability to produce high-resolution, three-dimensional images, which can 
visualize and obtain the three- dimensional measurements of invasive tumor without 
cutting the tumor as is the case in the pathology procedure. Few studies have applied 
Micro CT technology to assess the interior structure of breast tissue. 38,39   These studies 
suggested that Micro CT is capable of identifying the different components of breast 
tissue as well as differentiating between benign and malignant breast tumor. However, 
none of these studies measured the malignant tumor size because they were performed on 
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breast core biopsy specimens, which contain only a representative section of the breast 
lesion. Since none of the previous modalities were helpful to the pathologist for tumor 
measurement, there exists a need to find a new modality, such as Micro CT, which could 
help to confirm the final pathological tumor size measurement in cases where the 
invasive tumor size could be larger or smaller than gross examination would demonstrate 
in order to provide the patients with appropriate treatment.   
 
The purpose of this study To assess the ability of Micro Computed Tomography 
(Micro-CT) to measure malignant tumor size in breast lumpectomy specimens, as 
compared to the histopathological results. 
 
The primary study question: To what extent does the Micro Computed Tomography 
(Micro CT) scan give an accurate measurement of invasive breast cancer size in 
lumpectomy specimens compared to pathological assessment (the gold standard) among 
women aged 18 years and older at the Massachusetts General Hospital? 
 
The primary study objective: To determine whether there is an agreement between 
Micro-CT scan and histopathology assessment regarding the linear measurement of the 
primary breast cancer size. 
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The study endpoints/outcome of interest: The length of the longest linear measurement 
across the breast tumor size that is obtained from Micro-CT scan and the pathology 
reports of all subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
26 
2. METHODS  
 
This study was approved by the Massachusetts General Hospital (MGH) 
Institutional Review Board (IRB). Women who were scheduled to have breast 
lumpectomy surgery at the Massachusetts General Hospital Department of surgery from 
June 2011 – September 2011 and who met the inclusion and exclusion criteria were 
recruited for study participation. All the participants were consented prior their 
participation in this study on the day of the surgery, specifically in the early morning. 
Demographic information of each subject such as age, race, menopausal status, 
and family history of breast cancer were obtained through the medical records. In 
addition, the pathology report of each subject was reviewed. Information cancer type, 
tumor size, and grade, were collected from the pathology reports. Medical records and the 
pathology reports were reviewed after recording the Micro CT tumor size measurement 
of all subjects. 
 
2.1 Study Population 
Inclusion Criteria 
1) Women aged 18 years old or older from the date of consent. We choose this age 
because we do not want to include children in our study, and breast cancer is 
uncommon in women younger than 18. Hence these women were not part of our 
targeted population. 
2) Confirmed diagnosis of invasive breast carcinoma by biopsy. 
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Exclusion Criteria 
 
1) Women who were scheduled to have a re-excision surgery. Because the 
lumpectomy specimen will not contain the primary tumor, so, the measurement 
would not be performed. 
2) Women whose final diagnosis was only in situ disease. The staging of the in situ 
depends on the type of the in situ component, not the size of the tumor. 
3) Subjects who were unable to provide informed consent. In order to conduct an 
ethical clinical study, respect of persons and providing extra protection of those 
with diminished autonomy is required. 
 
2.2 Study Design 
A diagnostic study was conducted to assess the ability of Micro-CT scanning to 
accurately measure the breast malignant tumor size in excised lumpectomy specimens, 
and to compare these measurements with the pathological breast malignant tumor sizes 
described in the pathology reports. No randomization was applied. 
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2.3 The Measurements Methods 
          2.3.1 Micro CT measurements 
On the day of the surgery, the machine was calibrated early in the morning. Once 
the breast malignant tumor was removed from the patient, it was transferred immediately 
to our lab for scanning. Dedicated Micro CT technicians scanned the entire excised 
lumpectomy specimen using a tabletop Micro-CT Skyscan 1173 (Skyscan, Belgium). The 
machine is composed of an X-ray microfocus tube, a rotatory movable stage, and a 
detector. The X-ray tube has voltage of 40-130 Kv (Kilo Volt), and 8 W (Watt) x-ray 
sources. The X-rays generated were cone-beam rays.  
 
The specimens were scanned inside a transparent container for no longer than 15 
minutes. The scanning time ranged from 7 minutes to 14 minutes. Each specimen was 
rotated 360 0 with an incremental rotation step of 0.40 0 to 0.80 0.  
 
The localized needle wire was removed from the specimens before they were 
scanned in order to avoid the image artifact, which would cause misspresentation of the 
specimen structure in the image. After the scan was completed, the excised specimens 
were delivered to the pathology grossing lab, where it was processed via standard 
pathological protocol. 
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Later, Micro-CT technicians assembled a three-dimensional image representation 
of the specimen from the raw scan data using Skyscan’s NRecon program. 
 
The reconstructed images were analyzed using Skyscan’s software called Data 
Viewer and CTVox. The three dimensional images of the malignant tumor were obtained 
using the same software. This software provides tools to analyze the 3D images of the 
tumor.  
The images were previewed from three orthogonal perspectives: from the X-rays 
source, from Micro CT window in the right side, and from the top down. Before the 
linear measurement was obtained, the measurement tool was calibrated by centimeters 
(cm). A single linear measurement of the largest diameter of the tumor was taken after 
identifying the tumor edges in the Micro CT image. 
 
An independent physician who received training in reading the Micro CT images 
performed the invasive tumor measurement. In addition, the physician was blinded to the 
histopathology results and the medical records to avoid measurement bias.   
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         2.3.2 Gross measurements 
The gross examination was performed by a single, different pathologist each time. 
The specimen was received fresh with no fixative solution added to it. The complete 
description of the specimen shape, size, consistency, and color was recorded and 
documented. If the specimen was not oriented, it was entirely inked black. If the 
specimen was oriented, it was inked with six different colors. The specimen was then cut 
into uniform 2-mm thick serial sections along its longest axis. Once the tumor was 
identified by naked eyes in the sectioned tissue, gross three-dimensional measurements 
were taken in centimeters (cm), using blue plastic ruler. 
 
In some situations, the microscopic measurement was used when the tumor was 
too small to detect by the naked eye, or when the tumor had a diffuse growth pattern and 
less circumscribed borders. 
 
2.3.3 Comparison Methods 
To compare the breast malignant tumor size, the largest dimension of the tumor 
from the Micro CT was compared with the largest tumor dimension from the pathology 
report. 
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2.4 Statistical data analysis 
For descriptive analysis of the sample features, mean, standard deviation, and 
percentage were calculated.  
 
For the primary outcome measures, the percentages of the Micro CT cases that 
overestimated, underestimated, and matched tumor size compared to the pathological 
tumor size were calculated. The match cases were defined as the Micro CT tumor size 
cases that matched to the pathological tumor size cases nearest first decimal point. In 
addition, a student-paired t-test was performed to assess the difference in tumor size 
measurement between the Micro CT and pathology. 
 
The study subjects were categorized into two groups based on invasive tumor 
maximum dimension in the TNM classification. Group 1 contained subjects with tumor 
maximum dimension less than or equal to 2 cm, and group 2 contained subjects with 
tumor maximum dimension greater than 2cm. Validity measurements such as sensitivity 
and specificity, positive predictive value (PPV), and negative predictive value (NPV) 
were calculated with 95% confidence intervals. Group 1 with tumor size less than or 
equal to 2 cm was treated as a positive result. The reason behind this was to evaluate the 
ability of Micro CT to detect the tumor size with maximum dimension ≤ 2cm in across. 
To measure the agreement between the two categories, Cohen’s-kappa was calculated 
with 95% confidence intervals. 
	  32 
 
To assess the agreement graphically between the Micro CT and pathology in 
measuring the maximum dimension of the invasive tumor, an Altman-Bland plot with 
95% limit of agreement was generated. 
 
In addition, the study subjects were first categorized into two groups, and then 
categorized into four groups based on the T-staging, which was obtained from greatest 
dimension of the invasive tumor measured by Micro CT. The Micro CT T-stage was 
compared to the pathological T-stage to assess the underclassification and 
overclassification. The number and percent of cases that showed changes in the T stage 
were calculated. To measure the agreement between the categories, Cohen-kappa was 
calculated with 95% confidence intervals. 
P-values less than or equal to 0.05 were considered statistically significant. 
All the study analyses were carried out using R version 3.0.3.40 
 
2.5    Sample size 
To our knowledge, we are the first to conduct a study regarding the ability of 
Micro CT to perform accurate tumor measurement. . Because this was a pilot study, 
power calculations were not feasible. A total of 45 subjects who met our eligibility 
criteria were enrolled. 
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3. STUDY RESULTS 
     3.1 Study Sample Characteristics 
Forty-five female subjects who were diagnosed with primary invasive breast 
cancer and underwent breast lumpectomy were included in this study. A general 
description of the study sample is found in Table 2 
 
Table 2. Study Sample Features 
 
Features Case 
N= 45 
Demographics 
Age, yr 
Age, N (%) 
30-39 
40-49 
50-59 
60-69 
70-79 
80-89 
 
61.42 ± 12.05 
 
1   (2.2) 
8   (18) 
10  (22) 
15  (33) 
8   (18) 
3   (6.7) 
Race, N (%) 
Asian 
Black 
Non-Hispanic white 
 
1   (2.2) 
5   (11) 
39  (87) 
Menopausal Status, N (%) 
Premenopausal 
Postmenopausal 
 
9    (20) 
36  (80) 
Cancer detection method, N (%) 
Screening mammography 
Palpable mass 
 
31  (69) 
14   (31) 
Type of Cancer, N (%) 
Invasive ductal carcinoma (IDC) 
Invasive lobular carcinoma (ILC) 
 
39   (87) 
  6    (13) 
Grade of IDC, N (%) 
Grade 1 
 
5     (13) 
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Grade 2 
Grade 3 
23    (59) 
11     (28) 
Grade of ILC, N (%) 
 Grade 2 
 
6 (100) 
Type of In situ component within the 
cancer, N (%) 
Ductal carcinoma in situ (DCIS) 
    IDC                                             
    ILC 
Lobular carcinoma in situ (LCIS) 
    IDC  
    ILC 
Both DCIS & LCIS 
     IDC 
     ILC 
 
 
33(85) 
1(17) 
 
2 (5) 
6(100) 
 
7(18) 
1(17) 
Grade of Ductal Carcinoma in situ, N (%) 
Grade 1 
Grade 2 
Grade 3 
Unknown 
 
5 (11) 
15 (33) 
11 (24) 
2 (4.4) 
Other findings in the breast cancer, N (%) 
 Healing tissue 
 Benign lesion 
 
43(96) 
24(53) 
                
Pathological T-stage, N (%) 
   T1a 
   T1b 
   T1c 
   T2 
 
  3    (6.7) 
  8    (18) 
                             23   (51) 
                             11  (24) 
Note: 1) Percentages are based on the total number of each group 
          2) All percentages were rounded to 2 digits 
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3.2 Micro CT – pathological agreement 
Micro CT measurement of the invasive tumor maximum dimension ranged from 
0.4 to 3.1 cm with an average of 1.582 cm (SD ± 0.69), while the pathology measurement 
of invasive tumor maximum dimension ranged from 0.25 to 3.5 cm with an average of 
1.447 cm (SD ± 0.66). Means and standard deviation of IDC and ILC are found in Table 
3.  
Table 3. Micro CT tumor size mean compared to pathology tumor size mean in IDC 
and ILC. 
 
Breast Cancer type Micro CT tumor size (cm) 
Mean (SD) 
Pathology tumor size (cm) 
Mean (SD) 
IDC 1.505(± 0.65) 1.458 (± 0.67) 
ILC 2.083 (± 0.75) 1.375 (± 0.71) 
 
Micro CT measurement underestimated pathology tumor size measurement in 17 
cases (38%), overestimated it in 24 cases (53%), and matched it exactly in 4 cases 
(8.9%). For invasive ductal carcinoma, the Micro CT measurement underestimated 
pathology tumor size measurement in 15 cases out of 39 cases (38%), overestimated it in 
20 cases (51%), and matched it exactly in 4 cases (10%). For invasive lobular carcinoma, 
the Micro CT measurement underestimated the pathology tumor size measurement in 2 
cases out of six cases (33%), overestimated it in 4 cases (67%), and did not match it in 
any cases. See Table 4 for more information. 
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Table 4. Comparison of tumor size measurement between Micro CT and pathology 
 
Group Underestimate (%) Overestimate (%) Match (%) 
All 17 (38) 24 (53) 4 (8.9) 
IDC 15 (38) 20 (51) 4 (10) 
ILC 2 (33) 4 (67) 0 
Note: 1) Percentages are based on the total number of each group 
    2) All percentages were rounded to 2 digits 
          3) The match cases were defined as the Micro CT tumor size cases that matched to   
the pathological tumor size cases at nearest first decimal point 
 
A paired t-test was performed to assess the mean difference between the Micro 
CT and pathological tumor size measurements in the both types of breast cancer. IDCs 
exhibited the lowest difference in the mean compared to all tumors and ILC group. 
However, the results were not statistically significant. Detailed information for the paired 
t-test is found in Table 5. 
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Table 5. Paired t-test statistics for comparison of Micro CT and pathological tumor 
size 
Group Mean of differences, in cm 
(95% CI) 
P-value 
All 0.1  (-0.04 – 0.31) 0.1331 
IDC 0.04  (-0.07- 0.17) 0.4424 
ILC 0.7  (-0.59 – 2.01) 0.2217 
 
 
Based on Micro CT measurement of the invasive tumor greatest dimension and 
TNM staging system, we divided the subjects into two groups: Group 1contained 35 
(78%) subjects with invasive tumor maximum dimension size ≤ 2cm, Group 2 contained 
10 subjects (22%) with invasive tumor maximum dimension > 2cm. More information 
about the two groups is found in Table 6.  
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Table 6. Cross tabulation of invasive tumor maximum dimension groups between 
Micro CT and pathology 
                                                                                    Pathological tumor size group 
 
   
                                 
 
Micro CT tumor 
size group 
 
Tumor size group           ≤ 2cm                   > 2cm 
 
≤ 2cm          30 5 
> 2cm                                      4                                          6 
 
                Pathological tumor size group in IDC 
 
 
                                   
 
Micro CT tumor 
size group in IDC 
Tumor size group           ≤ 2cm                   > 2cm 
 
≤ 2cm          28 4 
> 2cm                                      1                                          6 
 
Pathological tumor size group in ILC 
 
 
 
 
Micro CT tumor 
size group in ILC 
 
Tumor size group           ≤ 2cm                   > 2cm 
 
≤ 2cm           2 1 
> 2cm                                      3                                          0 
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Validity measurements were calculated for the subjects based on this cross 
tabulation. Tumor ≤ 2 cm were considered as a positive test. In addition, the validity 
measurements were performed for IDC, and ILC. The results of the validity 
measurements are found in Table 7. 
 
Table 7. Validity Measurements of Micro CT tumor size group compared to 
pathological tumor size group 
Validity 
Measurement 
All (95% CI) IDC (95% CI) ILC (95% CI) 
Sensitivity  0.88 (0.73, 0.97) 0.97 (0.82, 1.00) 0.40 (0.05, 0.85) 
Specificity  0.55 (0.23, 0.83) 0.60 (0.26, 0.88) 0.00 (0.00, 0.99) 
PPV  0.86 (0.70, 0.95) 0.88 (0.71, 0.96) 0.67 (0.09, 0.99) 
NPV  0.60 (0.26, 0.88) 0.86 (0.42, 1.00) 0.00 (0.00, 0.81) 
Note: Tumor ≤ 2 cm were considered as a positive test. 
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The Kappa statistic was calculated for the invasive tumor size group to assess the 
interrater agreement, demonstrating a statistically significant moderate agreement (κ = 
0.44) for all invasive tumors, a statistically significant substantial agreement for IDC (κ = 
0.66), and no agreement for ILC (κ = -0.33). However, ILC agreement result was not 
statistically significant. Detailed information on kappa statistics of the groups is found in 
Table 8. 
 
 Table 8. Kappa statistics for invasive tumor size group in IDC, and ILC 
Groups Kappa Coefficient (CI) P-value 
 
All 
 
0.44 (0.11 – 0.76) 
 
0.01351 
 
IDC 
 
0.62 (0.32 – 0.93) 
 
0.00229 
ILC -0.3 (-1.08 - 0.42) 0.7929 
 
 
 
 
The Bland-Altman plot (Figure 10) showed that the 95% limit of agreement 
between Micro CT and pathology measurements for all breast cancer types was -1 to 1.3 
cm,  -0.7 to 0.7cm for invasive ductal carcinoma, and -1.7 to 3.1cm for invasive lobular 
carcinoma. See Figure 10 for more information.  
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                                                               (A) 
 
                           (B)                                                                   (C) 
Figure 10. Bland Altman plots illustrating the size difference between the 
Micro CT and pathology against the size average of Micro CT and pathology. (A) 
For the all types of breast cancer. (B) For IDC, (C) For ILC. 
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For Micro CT alteration of the pathology T-stage classification, 17 cases (38%) 
showed T-stage changes, with 10 cases out of 17 cases (59%) changed into a higher 
stage, and 7 cases (41%) changed into a lower stage. For IDC, T-stage changed in 12 out 
of 39 cases (31%) after comparing the Micro CT tumor size to the pathological tumor 
size, with 8 out of 21 cases (67%%) changed into a higher stage, 4 cases (33%) changed 
into a lower stage. However, 27 out of 39 cases (69%) showed no change in the T-stage. 
For ILC, T-stage changed in 4 out of 6 cases (67%) after comparing the Micro CT tumor 
size to the pathological tumor size, with 3 out of 4 cases (75%) changed into a lower 
stage, 1 case (25%) into a higher stage. However, 2 out of 6 cases (33%) showed no T-
stage alteration. 
 
Table 9. Comparison of T-stage classification between Micro CT and pathology 
      
Tumor 
type 
No change (%) Changed 
(%) 
Higher (%) Lower (%) 
All 28 (62) 17 (38) 10 (59) 7 (41) 
IDC 27 (69) 12 (31) 8 (67) 4 (33) 
ILC 2 (33) 4 (67) 1 (25) 3 (75) 
  Note: the percentage based on the total number of the subjects on each group 
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Based on Micro CT measurement of the invasive tumor maximum dimension and 
TNM staging system, the subjects were classified into two staging groups: T1 and T2. 
Because the T1 stage is subdivided into three further groups, subjects in T1 group were 
subdivided into these groups. Detailed information of T-staging groups and T1 sub-
staging groups are found in Table 10,11. 
 
Table 10. Cross tabulation of T- stage groups between Micro CT and pathology 
 
Pathological T staging 
 
                                   
 
Micro CT T 
staging  
 
T- staging group                T1                       T2 
 
T1                   30  5 
T2                                    4                                           6 
                                     Pathological T staging for IDC 
 
                                  
Micro CT T 
staging for IDC 
 
T- staging group                        T1                                        T2 
                                                                    
T1                   28  4 
T2                                    1                                           6 
               Pathological T staging for ILC  
 
                                
 
Micro CT T 
staging for ILC  
 
T- staging group                        T1                                         T2 
                                                                  
T1                   2  1 
       T2                                         3                                            0  
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Table 11. Cross tabulation of T1 subgroups and T2 group between Micro CT and 
pathology 
 
      Pathological T1 staging  
      
 
 
 
Micro CT 
T1 staging 
 
T-staging 
group 
 
T1a 
 
T1b 
 
T1c 
 
T2 
T1a 1 2 1 0 
   T1b 0 3 2 0 
T1c 1 2 18 5 
              T2 1 1 2 6 
Pathological T1 staging for IDC 
  
 
 
 
Micro CT 
T1 staging 
for IDC 
 
T-stage 
group  
 
T1a 
 
T1b 
 
T1c 
 
T2 
T1a 1 2 1 0 
T1b 0 3 2 0 
T1c 1 2 16 4 
6 T2 0 0 1 
Pathological T staging for ILC 
  
 
 
 
Micro CT 
T1 staging 
for ILC 
 
T-staging 
group 
 
T1a 
 
T1b 
 
T1c 
 
T2 
T1a 0 0 0 0 
T1b 0 0 0 0 
T1c 0 0 2 1 
T2 1 1 1 0 
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The kappa statistics of T-stage groups showed statistically significant moderate 
agreement (κ = 0.44, 95% CI 0.11 – 0.76). For T1-substaging groups, the kappa 
coefficient was 0.39, which indicated statistically significant fair agreement (p-value = 
0.0003122). Kappa statistics for both groups in IDC and ILC are found in Table 12, 13 
for both IDC and IL 
 
Table 12. Kappa Statistics for T-stage groups in IDC, and ILC. 
Groups Kappa Coefficient (CI) P-value 
 
All 
 
0.44 (0.11 – 0.76) 
 
0.01351 
 
IDC 
 
0.62 (0.32 – 0.93) 
 
0.00229 
ILC -0.3 (-1.08 - 0.42) 0.7929 
 
 
 
Table 13. Kappa Statistics for T1- substage groups in IDC, and ILC. 
Groups Kappa Coefficient (CI) P-value 
 
All 
 
0.39 (0.16- 0.62) 0.0003122 
IDC 
 
  0.46 (0.22 – 0.70) 9.322e-05 
ILC         -0.24 (-0.63 - 0.15) 0.8844555 
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4. DISCUSSION 
In this study, we examined the agreement between Micro CT and pathology 
measurement of the breast malignant tumor size in 45 subjects who had a confirmed 
diagnosis of primary breast cancer by histopathology. To our best knowledge, we are the 
first to report the use of Micro CT in assessing the breast malignant tumor size of 
lumpectomy specimens. Our study demonstrated that Micro CT overestimated the 
invasive tumor size in 24 cases out of 45 cases (53%). We would assume that Micro CT 
would underclassify the T-stage for the same number of cases after comparing to 
pathology. However, we found that Micro CT underclassified T-stage in only 7 out of 17 
(41%) cases in which Micro CT and pathology yielded a different T-stage classification. 
This could be explained by our finding that the difference between the Micro CT and the 
pathology measurements were within the value range of each stage, which could be 
considered as clinically irrelevant.  
 
The overestimation of invasive tumor size by Micro CT could be explained by 
underestimation of tumor size by pathological measurement due to tissue fixation in 
formalin and tissue processing. These factors could alter the microscopic tumor size 
measurement by causing tissue shrinkage. This affect can occur at any stage of the 
specimen processing from receiving the specimen in fixative solution to embedding the 
tissue in the paraffin blocks.41 One study reported a reduction of the pathological tumor 
size measurement between the fresh specimens and the final processed specimens in 
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40% of 50 breast cancer cases, with mean reduction ranging from1.7 mm to 2.4 mm 
from the fresh specimen measurement. 41 In our study, we were unable to eliminate this 
effect completely in eight cases where the tumor size was obtained only through 
microscopic measurement. However, for the rest of the cases, all the specimens were cut 
in the fresh state and measured during gross examination. 
 
Another explanation for the overestimation of tumor size could be due to other 
factors related to the lumpectomy procedure. The procedure can cause local bleeding 
and edema (swelling of the tissue due to accumulation of extracellular fluid). 42,43 In 
addition, a previous core biopsy may cause an inflammatory reaction and fibrosis that 
could result in tumor size overestimation by Micro CT.42, 43 
 
This study also demonstrated a statistically significant moderate agreement 
between Micro CT and pathology measurements regarding the maximum dimension of 
the invasive tumor, with substantial agreement for IDC measurement. However, there 
was no agreement for ILC measurement. Furthermore, ILC had the greatest mean 
difference between Micro CT and pathology measurement. Furthermore, ILC had the 
greatest mean difference between Micro CT and pathology measurement.  
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Based on the pathology reports, there were 34 tumors that measured ≤ 2cm. 
Micro CT identified 35 tumors measuring ≤ 2cm, corresponded to a sensitivity of 80%, a 
specificity of 55%, a PPV of 86%, and a NPV of 60 %. The Micro CT sensitivity and 
specificity related to the invasive tumor maximum dimension were relatively high for 
the IDC group (96%, and 60%, respectively), as opposed to the ILC group, which had 
low sensitivity (40%) and no specificity at all. In addition, the PPV and NPV IDC group 
were (88% and 86%, respectively) compared to the ILC group (PPV = 67%, NPV = 
0%).  
 
These observations could be explained by the growth nature of ILC, which has a 
diffuse, less circumscribed growth pattern without forming any fibrosis, thus 
complicating identification of ILC margins in the images. 19 Hence, the Micro CT 
measured IDC more accurately than ILC. The small number of ILC cases in the study 
compared to IDC may also explain the lack of agreement between Micro CT and 
pathology measurements of ILC tumor size. 
 
Micro CT and pathology demonstrated a statistically significant moderate 
agreement demonstrated moderate agreement in classifying cases into two T-stage 
groups. For IDC, the agreement was a substantial for two T- stage group classification, 
but dropped to moderate for the subdivided T-stage group classification. This is due to 
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the narrower range of tumor sizes in the subdivided T-stage groups compared to the two 
T-stage classifications. 
 
Nowadays, the pathologist plays a major role in breast cancer management by 
reporting the accurate measurement of breast cancer size in order to stage and to predict 
the prognosis of the disease.19 However, the pathologist cannot always report the final 
tumor size measurement accurately due to factors affecting the gross measurement such 
as small tumor sizes that are undetectable grossly, extensive hemorrhaging within the 
tumor, and the histology and growth pattern of the cancer. 19 Because the pathologist is 
required to report the best possible tumor size measurement, the pathologist will often 
use imaging modalities to support the measurement. Micro CT can be helpful to the 
pathologist in cases where the tumor size is uncertain, thus supporting the pathologist in 
staging the tumor and determining the appropriate treatment options for the patients. 
Therefore, Micro CT can serve as a clinical decision support system for measurement 
and staging of invasive breast cancers. 
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4.1 Study limitations and strengths  
The first limitation of this study was the small sample size. Because this 
technology is not a part of standard care, few subjects were enrolled in this study. 
Therefore, additional assessment of Micro CT using a large sample size is required to 
validate the study results. In addition, the small sample size and lack of power could 
explain the lack of statistically significant difference between the two methods. 
However, valuable information was obtained from this study such as validity 
measurements of Micro CT, which showed that Micro CT had high sensitivity in 
detecting IDC ≤ 2cm. However, we cannot rely on the ILC group results because the 
sample was pretty small. Therefore, a conclusion cannot be made regarding the ILC 
group, and further research is required to assess the ability of Micro CT to measure ILC 
in a large sample size. 
 
The second limitation is that the study results can only be generalized to 
postmenopausal women with early stage of breast cancer who were treated at the 
Massachusetts General Hospital. Because of this, the study sample is not representative 
of the target population. Hence, great caution should be considered when interpreting 
these findings. 
 
Third, although pathology is the gold standard in measuring the invasive tumor 
size, the possibility of variation in tumor size measurement by pathology cannot be 
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excluded because different pathologists performed the tumor size measurement in our 
study, which could affect the internal validity of these measurements. However, a 
previous study that was conducted by NHS breast cancer screening program to assess 
the performance of pathologists by circulating standardized breast cancer slides found 
greater than 90% agreement between pathologists in measuring tumor size 44. In 
addition, the pathologists at the MGH Department of Pathology follow specific 
guidelines regarding measurement of the tumor size. However, this limitation could 
affect our results. 
 
Forth, because of the small sample size, we were unable to evaluate the effect of 
the breast cancer grade and presence and percentage of carcinoma in situ components 
(DCIS and LCIS) in measuring tumor size. These factors could have contributed to 
errors in Micro CT invasive tumor size measurement toward the overestimation of tumor 
size using Micro CT measurement.  
 
Even with these limitations, this study had strengths. First, the Micro CT 
measurements were performed by an independent physician who received appropriate 
training in reading the Micro CT images and measuring the tumor size. In addition, the 
physician was blinded to the pathology reports and medical records of the subjects. The 
Micro CT was also calibrated before scanning each lumpectomy specimen. By doing 
this, we assured that we did not introduce a measurement bias.  
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Second, because this study was a pilot, it will help to determine the appropriate 
sample size to assess the Micro CT breast tumor measurement for a larger study, in 
order to obtain meaningful results. Also, we were able to identify the study limitations 
that can be addressed in the larger study. 
 
4.2 Future directions 
 
Because our study sample size was small, it would be useful to conduct this study 
again with a larger cohort to support the study results. It would also be useful to assess 
Micro CT measurement of invasive tumor size in ILC in a larger sample size as well. 
Since there were only few premenopausal subjects, it would be interesting to evaluate the 
Micro CT in this group to see if the invasive tumor size measurement is affected by high 
glandular component in the breast. In addition evaluate the effect of the breast cancer 
grade and presence of in situ component on the invasive tumor size measurements. 
 
Furthermore, in our study, we mainly compared the gross pathological tumor size 
with the Micro CT tumor size. For our next step, we would like to compare the Micro CT 
measurement with the microscopic measurement, and assess level of agreement between 
these two methods. 
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Finally, a diagnostic study will be conducted to assess the ability of Micro CT, in 
comparison with MRI and pathology, to identify multifocal/multicenter malignant lesion 
in breast lumpectomy specimens. 
 
 
5. CONCLUSIONS 
 In our small study, although the Micro CT tends to overestimate the breast 
malignant tumor size, Micro CT has statistically significant moderate agreement with 
histopathological examination in measuring and staging the breast malignant tumors. 
This agreement increases for invasive ductal carcinomas as opposed to invasive lobular 
carcinoma, where no agreement is found. Further investigation is required to evaluate the 
Micro CT in measuring the invasive lobular carcinoma. 
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Appendix 1. 
 
 
 
Figure 2. Ductal Carcinoma in situ (DCIS).  
(Image Imported from www.cancer.gov) 
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Appendix 2. 
 
 
 
Figure 3. Lobular Carcinoma in situ (LCIS). 
(Image imported from www.cancer.gov) 
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Appendix 3 
 
Beast profile 
A. Duct, B. Lobules, C. Dilated Section to hold milk, D. Nipple, E. Fat, F. Pectoralis 
major muscle, G. Chest wall. 
Enlargement: 
A. Normal ductal cell, B. Ductal cancer cells breaking through the basement membrane 
C. Basement membrane 
 
Figure 4. Invasive Ductal Carcinoma (IDC) 
(Image imported from www.breastcancer.org) 
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Appendix 4. 
 
Beast profile 
A. Duct, B. Lobules, C Dilated Section to hold milk, D. Nipple, E. Fat, F. Pectoralis 
major muscle, G. Chest wall. 
Enlargement: 
A. Normal ductal cell, B. Lobular cancer cells breaking through the basement 
membrane, C. Basement membrane 
 
 
Figure 5. Invasive Lobular Carcinoma (ILC) 
(Image imported from www.breastcancer.org) 
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Appendix 5. The pathological stage of breast cancer 
(Adopted from www.cancer.org) 
The American Joint Committee on Cancer (AJCC) established the breast cancer 
TNM staging system. The TNM system includes three letters: T for size of the primary 
tumor, N for regional lymph nodes involvement, and M for distant metastasis. 45,46,47 
Primary Tumor (T) 
• TX: Primary tumor cannot be assessed. 
• T0: No evidence of primary tumor. 
• Tis: Carcinoma in situ disease such as DCIS, LCIS, or Paget disease. 
• T1: Tumor is less than or equal to 2 cm. it divided into 4 subgroups: 
o T1mic: Microinvasion of 0.1 cm or less across. 
o T1a: Tumor is greater than 0.1 cm and less than 0.5 cm across. 
o T1b: Tumor is greater than 0.5 cm, and less than 1 cm across. 
o T1c: Tumor is greater than 1cm and not greater than 2 cm across. 
• T2: Tumor is larger than 2 cm, and less than 5 cm across. 
• T3: Tumor is larger than 5 cm across. 
• T4: Tumor of any size growing into the chest wall or skin. T4 is divided into 4 
subgroups: 
o T4a: Extension to the chest wall, but not the pectoralis muscle. 
o T4b: Edema (including peau d ‘orange) and/or ulceration of the breast 
skin, and/or satellite skin nodules in the same breast. 
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o T4c: Both T4a and T4b 
o T4b: Inflammatory carcinoma. 
 
Regional Lymph node 
• Nx: Regional lymph nodes cannot be assessed. 
• N0: No Metastasis in regional lymph nodes. 
• N1: Metastasis to movable ipsilateral axillary lymph node(s) 
• N2: Metastasis to fixed or matted ipsilateral axillary lymph nodes, or to 
ipsilateral internal mammary lymph nodes that diagnosed clinically 
(clinical examination or imaging studies), in the absence of metastasis in 
axillary lymph nodes. N2 is divided into 2 subgroups. 
o N2a: Metastasis in ipsilateral axillary lymph nodes fixed to one 
another or to other structure.  
o N2b: Metastasis only to ipsilateral internal mammary lymph 
nodes that are diagnosed clinically, in the absence of metastasis in 
axillary lymph nodes. 
• N3: Metastasis in ipsilateral infraclavicular lymph node(s) with axillary 
lymph noes involvement, or metastasis in ipsilateral internal mammary 
lymph nodes with axillary lymph node involvement, or metastasis in 
ipsilateral supraclavicular lymph nodes with or without axillary lymph 
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nodes or internal mammary lymph nodes involvement. N3 is divided into 
three subgroups 
o N3a: Metastases in ipsilateral infraclavicular lymph node(s) 
o N3b: Metastases in ipsilateral internal mammary lymph node(s) 
and axillary lymph node(s). 
o N3c: Metastases in ipsilateral supraclavicular lymph node(s). 
 
Pathological Classification (pN): 
 The lymph nodes classification is based on axillary lymph node dissection with 
or without involvement of sentinel lymph node (SNL) dissection. However, if the 
classification is based only on the sentinel in lymph node biopsy, it labeled with letters 
(sn). For example, p 
N0 (I+) (sn). 
• pNx: Regional lymph nodes cannot be assessed (e.g., previously removed 
or not removed for pathologic study). 
• pN0: No regional lymph node metastasis identified histologically [No 
isolated tumor cells (ITC)]. 
(Note: ITCs are defined as a single tumor cells or small cell clusters ≤ 0.2 
mm. ITC can be detected under the microscope by staining the lymph 
node section either with the basic stains such as Hematoxylin and Eosin 
stain ( H &E), or with immunohistochemistry (IHC) stains. Also, it can 
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be detected by molecular methods such as reverse transcriptase-
polymerase chain reaction (RT-PCR). 
 
o pN0(I-): No malignant cells detected by histology (negative 
H&E, negative IHC) in regional lymph nodes. 
o pN0(I+): Clusters of malignant cells ≤0.2 mm, detected by H&E 
or IHC including ITC in regional lymph node. 
o pN0(mol-): No regional lymph node metastasis histologically and 
negative molecular finding by RT-PCR.  
o pN0(mol+): No regional lymph node metastasis histologically, 
but positive molecular finding by RT-PCR . 
 
• pN1: Micrometastasis, or metastasis in one to three axillary lymph nodes 
and/or metastases in internal mammary lymph nodes with metastases 
detected by sentinel lymph node (SLN) biopsy but not detected by 
physical examination or imaging studies. 
o pN1mic: Micrometastasis (greater than 0.2 mm but not greater 
than 2.0 mm). 
o pN1a: Metastases in one to three axillary lymph nodes, at least 
one metastasis >2.0 mm. 
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o pN1b: Metastasis in internal mammary lymph nodes with micro 
or macro metastasis detected by SLN biopsy, but not detected by 
physical examination or imaging studies. 
 
o pN1c: Metastasis in one to  three axillary lymph nodes and 
internal mammary lymph nodes with micro or macro metastasis 
detected by SLN biopsy, but not detected by physical examination 
or imaging studies. 
 
• pN2: Metastasis in four to nine axillary lymph nodes or metastasis in 
clinically detected internal mammary nodes in the absence of metastasis 
in axillary lymph nodes 
 
o pN2a: Metastasis in four to nine axillary lymph nodes with at 
least 1 tumor deposit  greater than 2 mm 
o pN2b: Metastasis in clinically detected internal mammary nodes 
in absence of metastasis in axillary lymph nodes 
• pN3: Metastases in ten or more axillary lymph nodes, or metastasis in 
infraclavicular lymph nodes, or metastasis in clinically detected internal 
mammary lymph nodes in the presence of positive axillary lymph nodes, 
or metastasis in three axillary nodes and internal mammary lymph nodes 
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with micro/ macro metastasis detected by SLN biopsy or metastasis in 
ipsilateral supraclavicular lymph nodes 
o pN3a: Metastasis in ten or more axillary lymph nodes with at 
least one tumor deposit less than 2 cm, or metastasis to 
infraclavicular lymph nodes. 
o pN3b:  Metastasis in clinically detected ipsilateral internal 
mammary lymph nodes with one or more positive axillary lymph 
nodes, or metastasis in more than three axillary lymph nodes and 
internal mammary lymph nodes with micro/macro metastasis  
detected by SNL biopsy. 
o pN3c: Metastases in ipsilateral supraclavicular lymph nodes 
 
Distant Metastasis 
• Mx: Presence of distant metastasis cannot be assessed 
• M0: No distant metastasis.  
• M1: Distant metastasis. 
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AJCC Breast Cancer Stage grouping 
Stage 0 Tis, N0, M0 
Stage IA 
Stage IB 
T1, N0, M0 
T0 or T1, N1mi, M0 
Stage IIA T0, N1, M0  
T1, N1 M0 
T2, N0, M0 
Stage IIB T2, N1, M0 
T3, N0, M0 
Stage IIIA T0, N2, M0 
T2, N2, M0 
T3, N1, M0 
T3, N2, M0 
Stage IIIB T4, N0, M0 
T4, N2, M0 
Stage IIIC any T, N3, M0 
Stage IV any T, any N, M1 
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List of Abbreviated Journal Titles 
 
• Acta Radiol                                                                                        Acta Radiologica 
• Am J Surg                                                                       .American Journal of Surgery 
• Arch Surg                                                                                      Archives of Surgery 
• BMJ                                                                                          British Medical Journal 
• Eur J Radiol                                                                  European Journal of Radiology 
• Eur J Surg Oncol                                             European Journal of Surgical Oncology 
• JAMA                                                    Journal of the American Medical Association 
• J Bone Miner Res                                              Journal of Bone and Mineral Research 
• J Clin Oncol                                                                    Journal of Clinical Oncology 
• J Microsco                                                                                 Journal of Microscopy 
• J Natl Cancer Inst                                            Journal of the National Cancer Institute 
• J Opt Soc Am                                              Journal of the Optical Society of America 
• J Ultrasound Med                                                    Journal of Ultrasound in Medicine 
• Mater charact                                                                       Materials Characterization 
• NEJM                                                                      New England Journal of Medicine 
• Phys Med Biol                                                           Physics in Medicine and Biology 
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